<unk> /homoharringtonine is indicated for use as a treatment for patients with chronic myeloid leukaemia who are resistant or intolerant of tyrosine kinase inhibitors. In June 2009, results of a long-term open label Phase II study were published, which investigated the use of<unk>  infusions in CML patients. After twelve months of treatment, about one third of patients showed a cytogenetic response. A study in patients who had failed imatinib and who had the drug resistant T315I mutation achieved cytogenetic response in 28% of patients and hematologic response in 80% of patients, according to preliminary data. Phase I studies including a small number of patients have shown benefit in treating myelodysplastic syndrome (MDS, 25 patients) and acute myelogenous leukaemia (AML, 76 patients). Patients with solid tumors did not benefit from<unk> .
Omacetaxine mepesuccinate
Viaspan
Ciltacabtagene autoleucel
Telotristat ethyl
Tecovirimat
Delamanid
Amantadine
Nalmefene